skip to main content
Idioma:
Resultados 1 2 3 next page
Refinado por: assunto: Cardiovascular System & Cardiology remover assunto: Cholesterol remover
Result Number Material Type Add to My Shelf Action Record Details and Options
1
2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk
2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk
Material Type:
Artigo 		Adicionar ao Meu Espaço

2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk

Lloyd-Jones, Donald M., MD, FACC ; Morris, Pamela B., MD, FACC ; Ballantyne, Christie M., MD, FACC ; Birtcher, Kim K., PharmD, AACC ; Daly, David D., MD ; DePalma, Sondra M., MHS, PA-C, CLS AACC ; Minissian, Margo B., PhDc, ACNP, AACC ; Orringer, Carl E., MD, FACC, FNLA ; Smith, Sidney C., MD, FACC

Journal of the American College of Cardiology, 2016-07, Vol.68 (1), p.92-125 [Periódico revisado por pares]

Elsevier Inc

Texto completo disponível

Citações Citado por
2
2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways
2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways
Material Type:
Artigo 		Adicionar ao Meu Espaço

2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways

Lloyd-Jones, Donald M ; Morris, Pamela B ; Ballantyne, Christie M ; Birtcher, Kim K ; Daly, Jr, David D ; DePalma, Sondra M ; Minissian, Margo B ; Orringer, Carl E ; Smith, Jr, Sidney C

Journal of the American College of Cardiology, 2017-10, Vol.70 (14), p.1785-1822 [Periódico revisado por pares]

United States: Elsevier Limited

Texto completo disponível

Citações Citado por
3
Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-IT
Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-IT
Material Type:
Artigo 		Adicionar ao Meu Espaço

Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-IT

Bhatt, Deepak L ; Steg, Ph Gabriel ; Miller, Michael ; Brinton, Eliot A ; Jacobson, Terry A ; Ketchum, Steven B ; Doyle, Jr, Ralph T ; Juliano, Rebecca A ; Jiao, Lixia ; Granowitz, Craig ; Tardif, Jean-Claude ; Gregson, John ; Pocock, Stuart J ; Ballantyne, Christie M

Journal of the American College of Cardiology, 2019-06, Vol.73 (22), p.2791-2802 [Periódico revisado por pares]

United States: Elsevier Limited

Texto completo disponível

Citações Citado por
4
Review of Clinical Practice Guidelines for the Management of LDL-Related Risk
Review of Clinical Practice Guidelines for the Management of LDL-Related Risk
Material Type:
Artigo 		Adicionar ao Meu Espaço

Review of Clinical Practice Guidelines for the Management of LDL-Related Risk

Morris, Pamela B., MD ; Ballantyne, Christie M., MD ; Birtcher, Kim K., MS, PharmD, CDE, BCPS ; Dunn, Steven P., PharmD, BCPS ; Urbina, Elaine M., MD, MS

Journal of the American College of Cardiology, 2014-07, Vol.64 (2), p.196-206 [Periódico revisado por pares]

New York, NY: Elsevier Inc

Texto completo disponível

Citações Citado por
5
Rationale and design of the dal-OUTCOMES trial: Efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome
Rationale and design of the dal-OUTCOMES trial: Efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome
Material Type:
Artigo 		Adicionar ao Meu Espaço

Rationale and design of the dal-OUTCOMES trial: Efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome

Schwartz, Gregory G., MD, PhD ; Olsson, Anders G., MD, PhD ; Ballantyne, Christie M., MD ; Barter, Phillip J., MD, PhD ; Holme, Ingar M., PhD ; Kallend, David, MB, BS ; Leiter, Lawrence A., MD ; Leitersdorf, Eran, MD ; McMurray, John J.V., MD ; Shah, Prediman K., MD ; Tardif, Jean-Claude, MD ; Chaitman, Bernard R., MD ; Duttlinger-Maddux, Regina, PhD ; Mathieson, John, PhD

The American heart journal, 2009-12, Vol.158 (6), p.896-901.e3 [Periódico revisado por pares]

United States: Mosby, Inc

Texto completo disponível

Citações Citado por
6
Preventive Cardiology as a Subspecialty of Cardiovascular Medicine: JACC Council Perspectives
Preventive Cardiology as a Subspecialty of Cardiovascular Medicine: JACC Council Perspectives
Material Type:
Artigo 		Adicionar ao Meu Espaço

Preventive Cardiology as a Subspecialty of Cardiovascular Medicine: JACC Council Perspectives

Shapiro, Michael D ; Maron, David J ; Morris, Pamela B ; Kosiborod, Mikhail ; Sandesara, Pratik B ; Virani, Salim S ; Khera, Amit ; Ballantyne, Christie M ; Baum, Seth J ; Sperling, Laurence S ; Bhatt, Deepak L ; Fazio, Sergio

Journal of the American College of Cardiology, 2019-10, Vol.74 (15), p.1926-1942 [Periódico revisado por pares]

United States: Elsevier Limited

Texto completo disponível

Citações Citado por
7
Estimation of Eligibility for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors and Associated Costs Based on the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk): Insights From the Department of Veterans Affairs
Estimation of Eligibility for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors and Associated Costs Based on the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk): Insights From the Department of Veterans Affairs
Material Type:
Artigo 		Adicionar ao Meu Espaço

Estimation of Eligibility for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors and Associated Costs Based on the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk): Insights From the Department of Veterans Affairs

Virani, Salim S ; Akeroyd, Julia M ; Nambi, Vijay ; Heidenreich, Paul A ; Morris, Pamela B ; Nasir, Khurram ; Michos, Erin D ; Bittner, Vera A ; Petersen, Laura A ; Ballantyne, Christie M

Circulation (New York, N.Y.), 2017-06, Vol.135 (25), p.2572-2574 [Periódico revisado por pares]

United States: by the American College of Cardiology Foundation and the American Heart Association, Inc

Texto completo disponível

Citações Citado por
8
Comparison of Longitudinal Skeletal Thigh Muscle Findings With Magnetic Resonance Imaging in Patients With Peripheral Artery Disease With–Versus–Without Diabetes Mellitus
Comparison of Longitudinal Skeletal Thigh Muscle Findings With Magnetic Resonance Imaging in Patients With Peripheral Artery Disease With–Versus–Without Diabetes Mellitus
Material Type:
Artigo 		Adicionar ao Meu Espaço

Comparison of Longitudinal Skeletal Thigh Muscle Findings With Magnetic Resonance Imaging in Patients With Peripheral Artery Disease With–Versus–Without Diabetes Mellitus

Gimnich, Olga A. ; Ortiz, Carlos B. ; Yang, Eric Y. ; Chen, Changyi ; Virani, Salim S. ; Kougias, Panos ; Lumsden, Alan B. ; Morrisett, Joel D. ; Ballantyne, Christie M. ; Nambi, Vijay ; Brunner, Gerd

The American journal of cardiology, 2022-10, Vol.181, p.130-138 [Periódico revisado por pares]

United States: Elsevier Inc

Texto completo disponível

Citações Citado por
9
2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk
2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk
Material Type:
Artigo 		Adicionar ao Meu Espaço

2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk

Lloyd-Jones, Donald M. ; Morris, Pamela B. ; Ballantyne, Christie M. ; Birtcher, Kim K. ; Covington, Ashleigh M. ; DePalma, Sondra M. ; Minissian, Margo B. ; Orringer, Carl E. ; Smith, Sidney C. ; Waring, Ashley Arana ; Wilkins, John T.

Journal of the American College of Cardiology, 2022-10, Vol.80 (14), p.1366-1418 [Periódico revisado por pares]

Elsevier Inc

Texto completo disponível

Citações Citado por
10
Very High-Risk ASCVD and Eligibility for Nonstatin Therapies Based on the 2018 AHA/ACC Cholesterol Guidelines
Very High-Risk ASCVD and Eligibility for Nonstatin Therapies Based on the 2018 AHA/ACC Cholesterol Guidelines
Material Type:
Artigo 		Adicionar ao Meu Espaço

Very High-Risk ASCVD and Eligibility for Nonstatin Therapies Based on the 2018 AHA/ACC Cholesterol Guidelines

Virani, Salim S. ; Akeroyd, Julia M. ; Smith, Sidney C. ; Al-Mallah, Mouaz ; Maddox, Thomas M. ; Morris, Pamela B. ; Petersen, Laura A. ; Ballantyne, Christie M. ; Grundy, Scott M. ; Stone, Neil J.

Journal of the American College of Cardiology, 2019-08, Vol.74 (5), p.712-714 [Periódico revisado por pares]

United States: Elsevier Inc

Texto completo disponível

Citações Citado por
Resultados 1 2 3 next page

Personalize Seus Resultados

  1. Editar

Refine Search Results

Expandir Meus Resultados

  1.   

Data de Publicação 

De até
Refinar
  1. Antes de2003  (3)
  2. 2003Até2007  (4)
  3. 2008Até2013  (4)
  4. 2014Até2018  (8)
  5. Após 2018  (6)
  6. Mais opções open sub menu

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.